The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
…, L Dirix, EF Solomayer, L Zorzino, L Darrigues… - Critical reviews in …, 2019 - Elsevier
Background The heterogeneity of metastatic breast cancer (MBC) necessitates novel
biomarkers allowing stratification of patients for treatment selection and drug development. We …
biomarkers allowing stratification of patients for treatment selection and drug development. We …
Publication trends in bariatric surgery: a bibliometric study
Y Dabi, L Darrigues, S Katsahian, D Azoulay… - Obesity surgery, 2016 - Springer
Background The interest in bariatric surgery has considerably increased in the scientific
community in the last two decades. We present a bibliometric analysis of scientific publications …
community in the last two decades. We present a bibliometric analysis of scientific publications …
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant …
AS Hamy, L Darrigues, E Laas, D De Croze, L Topciu… - PloS one, 2020 - journals.plos.org
Introduction The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant
chemotherapy (NAC). Its predictive value has not been validated on large cohorts with …
chemotherapy (NAC). Its predictive value has not been validated on large cohorts with …
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma
AS Hamy, GT Lam, E Laas, L Darrigues… - Breast Cancer Research …, 2018 - Springer
Purpose Few studies evaluated the prognostic value of the presence of lymphovascular
invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC). Methods The …
invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC). Methods The …
Interaction between molecular subtypes and stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy
…, D De Croze, E Laas, L Darrigues… - Clinical Cancer …, 2019 - AACR
Purpose: High levels of tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemotherapy
(NAC) are associated with higher pathologic complete response (pCR) rates and better …
(NAC) are associated with higher pathologic complete response (pCR) rates and better …
A single droplet digital PCR for ESR1 activating mutations detection in plasma
Activating mutations in the estrogen receptor 1 (ESR1) gene confer resistance to aromatase
inhibitors (AI), and may be targeted by selective estrogen receptor downregulators. We …
inhibitors (AI), and may be targeted by selective estrogen receptor downregulators. We …
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
L Darrigues, JY Pierga, A Bernard-Tessier… - Breast Cancer …, 2021 - Springer
Background Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6
inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard …
inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard …
Interactive exploration of a global clinical network from a large breast cancer cohort
Despite unprecedented amount of information now available in medical records, health
data remain underexploited due to their heterogeneity and complexity. Simple charts and …
data remain underexploited due to their heterogeneity and complexity. Simple charts and …
Evolution of synchronous female bilateral breast cancers and response to treatment
Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by
the same germline genetics and environmental exposures. Little evidence exists regarding …
the same germline genetics and environmental exposures. Little evidence exists regarding …
PD-L1 expression after neoadjuvant chemotherapy in triple-negative breast cancers is associated with aggressive residual disease, suggesting a potential for …
…, D Meseure, G Bataillon, E El-Alam, L Darrigues… - Cancers, 2021 - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICI) are now part of the therapeutical
arsenal for cancers at several sites and in several settings. PD-L1 expression is assessed to …
arsenal for cancers at several sites and in several settings. PD-L1 expression is assessed to …
